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ABSTRACT
Magnetite nanographene oxide has exhibited great potential in drug delivery and photothermal
therapy (PTT) for cancer treatment. Here we developed 5-fluorouracil-loaded poly (lactic-co-glycolic
acid)-coated magnetite nanographene oxide (NGO-SPION-PLGA-5-Fu) to simplify combined PTT and
chemotherapy in one complex. The nanocarrier was synthesized using a modified O1/W1/O2/W2 mul-
tiple emulsion solvent evaporation method and was characterized for size, zeta potential, drug loading,
in vitro and in vivo release. In this paper, in vivo suppression effect of PTT and chemotherapy using this
synthesized magnetite nanographene oxide was studied. The in vitro release of 5-Fu from nanoparticles
showed that 41.36% of the drug was released within 24h. In vivo release showed that 5-Fu has a sus-
tained release profile and prolonged lifetime in the rabbit plasma. Remarkably, a single injection of
NGO-SPION-PLGA-5-Fu and 808nm near-infrared laser (NIR) irradiation for 3min effectively suppressed
the growth of tumours compared with 5-Fu alone (p< .01). Magnetic resonance imaging (MRI) con-
firmed that the magnetic nanographene oxide was effectively targeted to the tumour site. Therefore,
NGO-SPION-PLGA-5-Fu showed excellent PTT efficacy, magnetic targeting property, and MRI ability, indi-
cating that there is a great potential of NGO-SPION-PLGA-5-Fu for cancer theranostic applications.
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Recently, hyperthermia (41–45 C) has proven to have syner-
gistic effects with traditional treatments such as chemother-
apy and radiotherapy [1]. Despite limited selectivity (to
cancer cells) of chemotherapy, which could lead to unex-
pected side effects to normal tissues [2], a combination of
chemotherapy and PTT is able to destroy cells as a minimally
invasive treatment methodology [3]. PTT is a local treatment
and only the area exposed to light is treated [4]. It is
expected that the effects of simultaneous chemotherapy and
heating on tumour cells can enhance the therapeutic gain;
also anticancer efficiency can significantly improve with tar-
geted chemotherapy and drug delivery to the specific tumour
region [5].
The fundamental characteristics of heating are denatur-
ation of cell proteins and increasing cell membrane perme-
ability, which is satisfactory for the penetration of drugs into
tissues [6]. Nowadays, more studies are focused on NIR-
absorbing photothermal agents to attend as heat carriers for
hyperthermia [7–10]. These materials, such as carbon nano-
tubes, gold nanomaterials and graphene, can strongly absorb
NIR light and convert it to heat energy to kill cancer cells
without affecting healthy tissues [11].
Recently, graphene-based nanomaterials have also
attracted interest in the field of biomedicine as they have
proven to be great candidates for drug and gene delivery
[12], and cancer phototherapies [13].
Graphene oxide (GO) sheets with outstanding high specific
surface area can interact with various biomolecules for the
application of in vitro and in vivo drug delivery [14]. Because
it has a high surface area and polyaromatic surface structure,
the loading capacity of nanographene oxide (NGO) is signifi-
cantly sufficient [15,16]. Moreover, the photothermal sensitiv-
ity of NGO and its optical absorption in the NIR region is
higher than in carbon nanotubes, which leads to photother-
mal ablation of tumours [10,17]. Additionally, because they
are hydrophilic groups on both sides of NGO they confirm
good stability and solubility in physiological solutions [18].
Nevertheless, the major drawback of GO is its toxicity in
biological systems [19]. To overcome this problem, nanoscale
GO is prepared with biocompatible coating such as poly (lac-
tic-co-glycolic acid) [20]. Much interest has been concentrated
on preparation of biodegradable and biocompatible PLGA
nanomaterials, owing to their potential utility in reducing
enzymatic degradation, encapsulation and sustained release
of various drugs, and higher drug payload and because they
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do not induce immune reactions or inflammation, increasing
efficacy of the treatment [21,22]. The US Federal Drug
Agency has approved the use of PLGA in medical applica-
tions. In the body, PLGA hydrolyses into the natural and bio-
degradable metabolites lactic acid and glycolic acid, resulting
in minimal systemic toxicity [23,24].
5-Fluorouracil is a pyrimidine analogue of the antimetabol-
ite anticancer drug class which is used in the treatment of
solid tumours such as colon cancer [25]. Wide distribution,
non-selectivity effect, and short plasma circulation half-life
(8–20min) of 5-Fu result in side effects and poor therapeutic
efficacy [26]. Therefore, 5-Fu was loaded onto the biodegrad-
able polymers or graphene sheets to extend its life time [27].
Dramatically, super paramagnetic iron oxide nanoparticles
(SPIONs), due to their special magnetic properties [28],
biocompatibility, chemical stability and relatively non-toxic
nature (in the body, SPIONs are metabolized into oxygen and
elemental iron by hydrolytic enzymes, where the iron accu-
mulates into the natural body stores) [29], have been applied
in many fields of biomedicine, such as magnetic resonance
imaging (MRI) contrast enhancement [30–32], targeted drug
delivery [33] and hyperthermia treatment of cancer [34].
The increasing use of core-shell nanoparticles with highly
controlled optical and magnetic properties has created good
attention for therapeutic applications and diagnosis (thera-
nostic agents) [35]. The GO–super paramagnetic iron oxide
nanoparticle (GO–SPION) composite has attracted extensive
attention because of its potential as a contrast agent for cell
labelling in MRI [36]. SPIONs produce strong hypointense
T2-weighted signal in MRI, which lead to non-invasive moni-
toring treatment response [37]. Moreover, active magnetic
targeting (by applying an external magnetic field) and PTT
treatment using SPIONs enhance the sensitivity and specifi-
city of the therapy [38].
To address these issue, in this study, a stepwise synthetic
method was designed to create a nanocomplex of NGO-SPION,
which was modified with a biocompatible polymer, PLGA and
used as the carrier for loading and delivery of 5-fluorouracil
with the aim to achieve highly efficient cancer chemotherapy
and PTT with minimal side effects in in vivo applications.
Materials and methods
Materials
Graphite powder, 5-fluorouracil, potassium permanganate
(KMnO4), and phosphoric acid (H3PO4) were purchased from
Sigma Chemical Company. Poly (lactic-co-glycolic acid) (PLGA)
was prepared from Boehringer-Ingelheim. Hydrogen peroxide
(H2O2), sulphuric acid (H2SO4), hydrochloric acid (HCl), iron (II)
chloride tetrahydrate (FeCl2.4H2O), iron (III) chloride hexahy-
drate (FeCl3.6H2O), oleic acid, ammonia solution (25 vol%),
dichloromethane, glycerine, Span60 and Tween60 were pur-
chased from Merck Chemical Company.
Cell culture materials such as Roswell Park Memorial
Institute (RPMI) 1640, penicillin–streptomycin solution, foetal
bovine serum (FBS), and Trypsin-EDTA (0.25%) were obtained
from Gibco. Mouse colon cancer cell line CT26 and Male
BALB/c mice were provided from Pasteur Institute of Iran.
Synthesis of magnetic NGO–PLGA-5-Fu
NGO-SPION-PLGA-5-Fu nanoparticles were prepared using a
modified O1/W1/O2/W2 multiple emulsion solvent evaporation
method (Scheme 1). Magnetite nanoparticles (Fe3O4) were
synthesized by co-precipitation method according to
Mahdavian et al. [39] report. Glycerine was used as a surfac-
tant to stabilize the dispersed phase. First, to prepare a pri-
mary organic phase, 20mg of magnetic nanoparticles was
dispersed in 0.5ml of dichloromethane (DCM) using a probe
ultrasonic (O1). Next, 5mg of GO was dispersed in 1.5ml of
deionized water and then 10mg of 5-Fu, as a hydrophilic
drug and 15mg Tween60, as a surfactant, were added to
inner aqueous solution (W1). Organic solution of the polymer
was prepared by dissolving 50mg PLGA and 250mg Span60
in 6ml DCM (O2). Finally, a W2 aqueous solution was pre-
pared of 150mg Tween 60 dissolved in 7.5ml of deionized
water (DW) and 7.5ml of glycerine. The magnetic dispersion
was emulsified in the inner aqueous solution by ultrasonica-
tion using the sonicator at an output of 50W for 30 s in an
ice-bath, to obtain an O1/W1 emulsion. This primary emulsion
Scheme 1. Schematic representation for the synthesis of NGO-SPION-PLGA-5-Fu.
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was emulsified in an organic solution (O2) of the polymer by
ultrasonication for 30 s (50W) in an ice-bath, to obtain an O1/
W1/O2 double emulsion. This double emulsion was immedi-
ately poured into W2 aqueous solution and the mixture was
ultrasonicated again for 30 s. Consequently, the multiple
emulsion (O1/W1/O2/W2) was diluted in 24ml of aqueous
solution containing 12ml DW and 12ml glycerine under
mechanical stirring for 3 h, and the DCM was removed by
solvent evaporation. Finally, the resulting nanoparticles were
washed by centrifugation and re-suspension in DW three
times and freeze-dried using Tajhizat Sazan Pishtaz Co, auto-
matic freeze-dryer (Iran). In addition, magnetic NGO–PLGA
nanoparticles were prepared using a similar technique, while
the inner aqueous solution (W1) was made in the same way,
but without 5-Fu.
Characterization of nanoparticles
Dynamic light scattering analysis was used to characterize the
hydrodynamic size and effective diameter of nanoparticles.
Also, the surface charge of the nanoparticles was investigated
by zeta potential measurement. The morphological investiga-
tion of nanoparticles was obtained using transmission elec-
tron microscope (TEM).
Drug content and encapsulation efficiency
To estimate the drug concentration in nanoparticles, a UV
absorption measurement was performed. First, a known
quantity of the nanocapsules was weighed and re-dissolved
in acetone. Next, the insoluble magnetite particles were
removed from the solution by magnetic separation. Finally,
the 5-Fu concentration in the acetone solution was deter-
mined by UV absorption at a wavelength of 265 nm (the
characteristic absorption band of 5-Fu), and the amount of
loading and encapsulated drug in the nanocapsules were cal-
culated using Equations (1) and (2).
Encapsulation efficiency
¼ Amount of 5 Fu in the nanoparticles
Total amount of 5 fu in dispersion  100
(1)
Drug loading efficiency
¼ Amount of 5 Fu in the nanoparticles
nanoparticles weight
 100 (2)
Also, survival was monitored daily and analysed using
Kaplan–Meier survival curves.
In vitro release study
The 5-Fu-loaded NGO-SPION-PLGA nanoparticles were trans-
ferred to phosphate buffered saline solutions (pH 7.4) (7mg/
mL) in a dialysis bag to evaluate the in vitro 5-Fu release
from NPs. The dialysis bag was placed fully into the release
medium (PBS) and incubated at 37 C at the shaking speed of
100 rpm. At appropriate time intervals (0, 1, 2, 3, 4, 6, 8, 12,
24, 48, 72, 96, 120–432 h) 2ml aliquots were withdrawn and
replaced with an equal volume of fresh medium. After col-
lecting samples, the concentration of released 5-Fu was
analysed using a UV visible spectrophotometer, subjected to
signal quantification with the absorption signal at 265 nm.
The 5-Fu release kinetics was calculated as a function of time.
In vivo release study
A single dose of 5-Fu alone and NGO-SPION-PLGA-5-Fu nano-
particles (5-Fu concentration of 3mg/kg) was administered
intravenously to female rabbits (n¼ 6). Two millilitres of
blood samples was collected from rabbit veins at 0.25, 0.5, 1,
2, 4, 8, 24, 96 and 168 h after injection. The samples were
extracted from plasma by mixing 250 lL of rabbit plasma
with 750 lL of acetonitrile. The mixture was vortexed for 20 s
and centrifuged for 10min at 4000 rpm; 500lL of super-
natant were dried under the steam of N2 at 87 C, and the
residue was dissolved in 150 lL of DW. Seventy microlitre of
the obtained solution was injected into the high-performance
liquid chromatography (HPLC). A reverse ACE5-C18
(250 4.6mm) column was used with a mobile phase of
0.01 M KH2PO4/DDW and a flow rate of 0.46ml/min at room
temperature. The absorbance at 265 nm was monitored, and
in vivo release profile was determined accordingly. The linear
equation of standard calibration curve of 5-Fu absorbance as
a function of 5-Fu concentration was y¼ 0.1697x4.3
(R2> 0.998). The lower limit of detection was 20 ng/mL.
Cell culture experiments
Mouse colon cancer CT26 cells were cultured in RPMI 1640
supplemented with 10% FBS, penicillin (100 units/mL), and
streptomycin (100mg/mL) in 5% CO2 and 95% air at 37 C in
a humidified incubator. Cells were harvested by trypsinizing
cultures with 1mM EDTA/0.25% trypsin (w/v) in PBS.
Xenograft tumour mouse model
Male BALB/c mice (6–8weeks old, 20–30 g) were housed
under controlled light, temperature and humidity conditions
for one week before use. All animal procedures were carried
out in accordance with the institutional Animal Care
Committee guidelines (approved by the Research Council of
Iran University of Medical Sciences). CT26 cells (3 106) in a
100 lL serum-free RMPI-1640 medium were injected subcuta-
neously onto the right flank of BALB/c mouse.
In vivo magnetic drug targeting
To assess the efficiency of nanocapsule localization in a
tumour site during the magnetic drug targeting (MDT) pro-
cedure, two tumours were established in a mouse bilaterally
(one in the right flank and one in the left flank). The initial
coronal and sagittal T2-weighted MR images of the mouse
were taken before NPs injection. Then, NGO-SPION-PLGA
nanoparticles were injected i.v. into the tail vein of the mouse
with concentration of 1.2mg in 100lL (0.28mg Fe3O4 in
100 lL). For targeting the NPs, the left tumour of the mouse
was exposed to an external magnetic field of 0.18 T for 2 h
(without applying to another tumour). Next, the same images
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were scanned again for both tumours. MR images were
obtained with a 3 Tesla MRI scanner and the following
parameters were used: TR: 6000ms, TE: 85ms, FA: 150.
Laser irradiation and temperature measurement study
NGO-SPION-PLGA suspensions in doubly DW (DDW) (1.2mg
in 100 lL) was injected subcutaneously after 2 h while apply-
ing local magnetic field of 0.18 T to the tumour tissue, and
irradiated with an 808 nm continuous-wave NIR laser with the
power of 0.8 W/cm2 and a spot size of 6 6mm (exposure
time 10min). The temperature was measured as a function of
time with an infra-red (IR) camera as real time.
In vivo antitumor effect
The mice were randomly divided into nine groups of five
mice, minimizing the differences of weights and tumour sizes
in each group. Theses nine groups were: (A) control, (B) mag-
netic field of 0.18 T, (C) irradiation of 808 nm NIR laser (0.8 W/
cm2, 8min), (D) magnetic field þ5-Fu (3mg/kg in 100lL), (E)
magnetic fieldþNGO-SPION-PLGA-5-Fu (1.2mg in 100 lL con-
taining 3mg/kg 5-Fu), (F) magnetic fieldþNGO-SPION-PLGA
(1.2mg in 100 lL), (G) magnetic fieldþNGO- SPION-PLGA-5-
FuþNIR (0.8 W/cm2, 3min), (H) magnetic fieldþNGO-SPION-
PLGAþNIR (0.8 W/cm2, 3min), (I) magnetic field þ5-FuþNIR
(0.8 W/cm2, 8min).
Drug and nanoparticles were injected intravenously into
the tail vein of the mice with a 5-Fu concentration of 3mg/
kg. After injection, in magnetic field group, a magnetic field
of 0.18 T was applied to the tumour for 2 h, and finally in
groups with NIR, the tumours were irradiated with an 808 nm
continuous-wave NIR laser with the power of 0.8 W/cm2 to
obtain 43 C (3-min and 8-min exposure for with and without
NPs injection, respectively). After treatment, tumour size was
measured in two dimensions by a caliper every 3 days, and
tumour volume (V) was calculated using Equation (3).
V ¼ tumor width
2
2
 tumor length (3)
Statistical analysis
All experiments were performed in triplicate and data are
presented as mean± SD. The tumour growth suppression
effect of the various treatment was analysed using one-way




The morphology of synthesized NGO-SPION-PLGA and NGO-
SPION-PLGA-5-Fu was observed using TEM images (Figure 1),
which showed the intact structures of GO sheets. Table 1
shows the size distribution and zeta potential values of nano-
particles of NGO-SPION-PLGA and NGO-SPION-PLGA-5-Fu. The
drug loading content and encapsulation efficiency of NGO-
SPION-PLGA-5-Fu was 5% and 50%, respectively.
In vitro release study
In vitro release of 5-Fu from NGO-SPION-PLGA-5-Fu was car-
ried out in a buffer solution (Figure 2). The results showed
the notable prolongation release of 5-Fu. At 37 C, the initial
release within the first 24 h was comparatively quick and
Figure 1. TEM images of the nanoparticles: (A) NGO-SPION-PLGA and (B) NGO-SPION-PLGA-5-Fu.
Table 1. Size and surface charge of nanoparticles.
Nanoparticle Size (nm) Zeta potential (mV)
NGO-SPION-PLGA 19.2 32.92 ± 1.04
NGO-SPION-PLGA-5-Fu 72.9 30.82 ± 0.57
Figure 2. The in vitro release profile of 5-Fu from NGO-SPION-PLGA-5-Fu.
The plot represents the mean ± standard deviation of the results.
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41.36% of loaded 5-Fu was released in 24 h. Then, continuous
and sustained release was observed over 16 days (54.6%
total release).
In vivo release study
The half-life of 5-Fu in plasma circulation is very short,
approximately 8–20min, therefore many reports have devel-
oped 5-Fu preparations with a prolonged lifetime. To
study the in vivo characteristics of the NGO-SPION-PLGA-5-Fu
nanoparticles, we administered 5-Fu alone and NGO-SPION-
PLGA-5-Fu nanoparticles to rabbits at a single 5-Fu dose
of 3mg/kg. Figure 3, illustrating 5-Fu alone followed a one-
compartment model. Nevertheless, the nanoparticles followed
a multi-compartment model, including burst release and sus-
tained release. The nanoparticles showed lower peak concen-
tration of 5-Fu as compared with free 5-Fu solution, and high
drug level was detected up to 4 h because of sustained
release of 5-Fu from the nanoparticles. Consequently, our
complex has a higher removal half-life.
In vivo magnetic drug targeting
Figure 4 shows T2-weighted MR images of CT-26 tumours
implanted in mice before and 2 h after nanoparticles injection
with concentration of 1.2mg in 100 lL. After i.v. injection of
magnetic nanoparticles, a permanent magnetic field of 0.18 T
was placed above the left tumour for 120min. In T2-weighted
fast spin echo images, accumulation of magnetic nanopar-
ticles in the tumour was seen as dark regions, showing that
NGO-SPION-PLGA nanoparticles were accurately targeted to
the desired location under the aid of an external magnetic
field and not systemically distributed.
Laser irradiation and temperature measurement study
In this study, the main objective of increasing temperature is
reaching 43 C. Before irradiation, the average of initial tem-
perature inside the tumours was 34.2 ± 1.2 C and interstitial
temperature was increased in time-dependent methods.
Figure 5(A) shows the effect of photothermal treatment using
an 808 nm laser by an IR thermal imaging system. Figure 5(B)
shows the increasing temperature profiles of the tumours
during the exposure time. The in vivo experiments demon-
strated that the presence of nanoparticles significantly enhan-
ces NIR-induced heat generation. The mean temperature of
tumours exposed to NIR alone was increased up to
43.5 ± 0.65 C at 8min. It was confirmed that administration
of NGO-SPION-PLGA and subsequent NIR irradiation heated
the CT26 tumours up to 43.3 ± 0.52 C at 3min.
Figure 3. The mean plasma concentrations of 5-Fu following i.v. administration
of 5-Fu and NGO-SPION-PLGA-5-Fu nanoparticles at a 5-Fu dose of 3mg/kg.
Figure 4. MRI scans of the mouse implanted with colon cancer (CT26 cell line): (A and C) coronal and sagittal scans before the injection of NPs and (B and D) cor-
onal and sagittal scans, 120min after the injection of NGO-SPION-PLGA nanoparticles. The new dark regions in the left tumour (indicated with an arrow) show the
accumulation of magnetic-NGO after the application of a magnetic field.
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In vivo antitumor effect
The efficacy of our nanocarriers in colon-bearing mice was
investigated in terms of tumour volume (mm3). Mice were
treated as mentioned in the “Materials and methods” section
to assess the therapeutic effects of NPs containing 5-Fu in
vivo. Figure 6 shows the effect of various treatment protocols
on CT26 tumour growth in Balb/c. There were no significant
differences between groups A (control), B (magnet), C (NIR),
D (NGO-SPION-PLGAþmagnet), E (5-FuþmagnetþNIR), and
F (5-Fuþmagnet) 21 days after start of treatments (p> .05).
However, there were significant differences (p< .01) between
group A (control), G (NGO-SPION-PLGA-5-Fuþmagnet), H
(NGO-SPION-PLGA-5-FuþmagnetþNIR), and I (NGO-SPION-
PLGAþmagnetþNIR). Our results showed that the average
tumour volume after treatment in group H was smaller com-
pared with the other treatment groups. In addition,
the rank of median survival time was NGO-SPION-PLGA-
5-Fuþmagnet (36 day)>NGO-SPION-PLGAþmagnetþNIR
(30 day)>magnetþ 5-FuþNIR (29 day)>Magnetþ 5-Fu
(28 day) >NGO-SPION-PLGAþmagnet (26 day)>NIR (25 day)
>Magnet (24 day)>Control (23 day) at 40 days follow up. By
the log-rank test, the median survival time NGO-SPION-PLGA-
5-FuþmagnetþNIR was significantly prolonged compared to
the rest (p< .05) (Figure 7(A)). Figure 7(B) shows the images
of tumours on mice after various treatments. The tumour was
suppressed with 5-Fu-NGO-SPION-PLGA treatment in com-
bined with laser irradiation.
Discussion
In the present study, NGO-SPION-PLGA nanoparticles have
been expended for the delivery of hydrophilic drug. Nano-GO
was negatively charged because of the presence of a
large number of –COOH groups [11]. Table 1 shows the char-
acteristics of NGO-SPION-PLGA and NGO-SPION-PLGA-5-Fu
nanoparticles.
Clinically, 5-Fu can be administered by continuous infu-
sion, which mostly prevents DNA synthesis, or by bolus injec-
tion, which mostly prevents RNA synthesis [40]. Because 5-Fu
is quickly metabolized in the body, a continuous high dose is
required to sustain a therapeutic serum level. Our results indi-
cated that when 5-Fu is loaded into nanoparticles, the 5-Fu
has a prolonged half-life and sustained-release. The in vitro
release was slow and only 54.6% of loaded 5-Fu was released
within 16 days (Figure 2), which is almost similar to other
studies [41,42]. It is worth noting that the pharmacokinetic
Figure 5. Laser irradiation and temperature measurement. (A) Effect of photothermal treatment using an 808 nm laser by an IR thermal imaging system.
(B) Temperature changes by NIR (808 nm, 0.8 w/cm2) with and without NGO-SPION-PLGA as a function of time in mice implanted with colon cancer.
Figure 6. Tumour growth suppression effects of various treatment protocols against CT26 tumour. The data represent the means ± SD, n¼ 3.
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characteristics of our 5-Fu-loaded NGO-SPION-PLGA nanopar-
ticles are approximately similar to the 5-Fu-loaded magnetic
PLGA nanoparticles of Shakeri-Zadeh et al. [43]. Based on
Figure 3, it is seen that when 5-Fu alone is administrated, the
plasma concentration of 5-Fu is rapidly decreased within 4 h,
whereas 5-Fu concentration in rabbit plasma increases and
then starts decreasing within 24 h in NGO-SPION-PLGA-5-Fu
administration. Hence, our in vivo studies indicate that when
5-Fu is loaded into NGO-SPION-PLGA nanoparticles, the 5-Fu
has a sustained release. It is remarkable that the pharmacoki-
netic characteristics of our 5-Fu-loaded NGO-SPION-PLGA
nanoparticles are similar to the 5-Fu-loaded 5-Fu/PEG-PBLG
nanoparticles of Li et al. [44].
In the case of photothermal treatment using an 808-nm
laser, we measured the real-time temperature changes of the
tumour tissue by an IR thermal imaging system (Figure 5(A)).
The NGO-SPION-PLGA nanoparticles may be effective thermal
generators, which could absorb NIR by the NGO and SPION
(Fe3O4) ingredients; these results are confirmed by studies
[45–47]. As a comparison, our colleagues reached tempera-
ture increasing by PTT treatment using a dose of 80 lg/mL of
nanographene oxide and 2min of laser exposure with the
power of 2W/cm2 in vitro.
Absorbed NIR promotes molecular alternation, leading to
efficient heating of the surrounding environment, which
could be employed as thermal ablation agents for thermal
destruction of tumours [11]. In mice injected with nanopar-
ticles (after magnetic targeting), the temperature of the
tumour started to increase as soon as laser irradiation began
and the temperature reached to 43 C after 3min of laser
exposure (Figure 5(B)). Whereas mice (without nanoparticles
injection) were treated with the same laser, temperature
increasing to 43 C was observed in 8min. It demonstrated
the excessive cumulating of NGO-SPION-PLGA inside the
tumour tissue and its capability to induce hyperthermia by
converting NIR light energy to heat in vivo. After the laser
treatments, mice were observed for 21 days; during this
period no mice died. This suggests that the i.v. injection of
nanoparticles was not significantly toxic to the mice. The size
of tumour was significantly suppressed in mice treated with
NGO-SPION-PLGA-5-Fuþmagnetic fieldþNIR. One obvious
observation was that there were black round indications on
the mice skins, a direct evidence of the tumour necrosis, and
this is due to origination of the extreme local heating from
NGO-SPION-PLGA by NIR laser irradiation (Figure 7).
Quantitative measurements showed that tumour volume
increased rapidly in the control groups, from about 140 mm3
to approximately 5000mm3. Strikingly, combined treatment
of the NGO-SPION-PLGA and NIR irradiation suppressed the
tumour within 21 days. The results suggested that the NGO-
SPION-PLGA-5-Fu nanoparticle was an effective agent for in
vivo PTT of cancer. Preceding reports have confirmed that
complete tumour ablation could be reached by PTT treat-
ment using NGO; the results were achieved using a high
dose of NGO and longer exposure to laser. As a comparison,
Zhang et al. reached a thorough tumour ablation by PTT
treatment using a dose of 10mg/kg of nanographene oxide
and 5min of laser exposure [2]. In contrast, the present study
reduced the dose of nanoparticles to 3mg/kg and the laser
irradiation was performed for 3min.
In addition, owing to the presence of iron oxide, our nano-
particles appeared in MRI images as dark regions that verify
the theranostic effect. Meanwhile, early reports have proven
this result [48,49]. The results demonstrate that combining
Figure 7. Effect of various treatments on survival of mice. (A) Kaplan–Meier survival curves of control and treated mice. (B) Representative photographs of tumours
on mice after various treatments.
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two therapeutic approaches into one system allowed us to
reduce the dose of nanoparticle as well as 5-Fu significantly,
but still achieved a highly efficient therapeutic performance.
Thus, we predict that NGO-SPION-PLGA mediated delivery of
5-Fu and combined phototherapy is a promising approach
for efficient tumour suppression.
Conclusions
In this study, we prepared 5-Fu-loaded NGO-SPION-PLGA
nanoparticles, which exhibited favourable pharmacokinetic
characteristics, including sustained drug release and pro-
longed drug half-life. In vivo, NGO-SPION-PLGA-5-Fu nanopar-
ticles had good anti-tumour activity against colon cancer
xenografts. Taken together, our results indicate that a NGO
nanoparticle delivery system for 5-Fu may be able to effect-
ively reduce contrary side effects of 5-Fu therapy and develop
the therapeutic index of 5-Fu. Consequently, in the in vivo
studies, NGO-SPION-PLGA-5-Fu showed excellent PTT efficacy,
magnetic targeting property, and MRI ability, indicating that
there is a great potential of NGO-SPION-PLGA-5-Fu for cancer
theranostic applications.
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